Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Description Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team